Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Experimental injection tested for debilitating muscle disease

NCT ID NCT06965309

Summary

This early-stage study tested an experimental injection called HN2301 in a small group of adults with severe, hard-to-treat myasthenia gravis. The main goal was to check if the treatment was safe and tolerable. Researchers also looked for early signs that it could help improve patients' muscle weakness and daily activities.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for REFRACTORY MYASTHENIA GRAVIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Shanghai General Hospital (Songjiang Branch) of Shanghai Jiao Tong University School of Medicine

    Shanghai, 201600, China

Conditions

Explore the condition pages connected to this study.